The Study of BCL11A Gene in Patients with Beta-Thalassemia Major and Intermedia by Random Amplephed Polymorphism DNA in Iraq

Thalassemia Autosomal recessive disorders occur due to mutations that lead to a decrease or absence of b-globin chains because mutations occur in the BCL11A gene being a potential therapeutic target to increase fetal hemoglobin levels in patients to reduce the severity of thalassemia symptoms. The study was designed to evaluate the relationship between the BCL11A gene polymorphism and its effect on the clinical features of patients with beta thalassemia major and intermedia. The whole blood DNA was extracted and an amplified gene was used as a template instead of the DNA genome in the RAPD technique PCR-RAPD-PCR, four primers (APAA11, APU15, APAA17, and APD18) to detect genetic polymorphism of BCL11A gene. The results showed that the number of bands in β-thalassemia major patients is more than the control group; there is also a difference in their molecular weights according to the type of the used primer. The results showed that there were statistically significant differences at the probability level of P< 0.05 in the total number of bands generated when using each primer separately between the patients and the control group.